Posttranslational modifications on proteins can serve as useful biomarkers for disease. However, their discovery and detection in biological fluids is challenging. Aptamers are oligonucleotide ligands that demonstrate high affinity toward their target proteins and can discriminate closely related proteins with superb specificity. Previously, we generated a cyclophilin B aptamer (M9-5) that could discriminate sera from pancreatic cancer patients and healthy volunteers with high specificity and sensitivity. In our present work we further characterize the aptamer and the target protein, cyclophilin B, and demonstrate that the aptamer could discriminate between cyclophilin B expressed in human cells versus bacteria. Using mass-spectrometric analysis, we discovered post-translational modifications on cyclophilin B that might be responsible for the M9-5 selectivity. The ability to distinguish between forms of the same protein with differing post-translational modifications is an important advantage of aptamers as tools for identification and detection of biomarkers.
Get full access to this article
View all access options for this article.
References
1.
ARIFM., SENAPATIP., SHANDILYAJ., and KUNDUT.K. (2010). Protein lysine acetylation in cellular function and its role in cancer manifestation. Biochim. Biophys. Acta, 1799, 702–716.
2.
BASKAK.M., MANANDHARG., FENGD., AGCAY., TENGOWSKIM.W., SUTOVSKYM., YIY.J., and SUTOVSKYP. (2008). Mechanism of extracellular ubiquitination in the mammalian epididymis. J. Cell Physiol., 215, 684–696.
3.
BLOWN. (2007). Antibodies: the generation game. Nature, 447, 741–744.
4.
CONRADR., KERANENL.M., ELLINGTONA.D., and NEWTONA.C. (1994). Isozyme-specific inhibition of protein kinase C by RNA aptamers. J. Biol. Chem., 269, 32051–32054.
5.
ELLINGTONA.D., and SZOSTAKJ.W. (1990). In vitro selection of RNA molecules that bind specific ligands. Nature, 346, 818–822.
6.
HELDD.M., KISSELJ.D., THACKERS.J., MICHALOWSKID., SARAND., JIJ., HARDYR.W., ROSSIJ.J., and BURKED.H. (2007). Cross-clade inhibition of recombinant human immunodeficiency virus type 1 (HIV-1), HIV-2, and simian immunodeficiency virus SIVcpz reverse transcriptases by RNA pseudoknot aptamers. J. Virol., 81, 5375–5384.
7.
HUANGFUW.C., QIANJ., LIUC., RUIH., and FUCHSS.Y. (2010). Melanoma cell-secreted soluble factor that stimulates ubiquitination and degradation of the interferon alpha receptor and attenuates its signaling. Pigment Cell Melanoma Res., 23, 838–840.
8.
ISHIZAKIJ., NEVINSJ.R., and SULLENGERB.A. (1996). Inhibition of cell proliferation by an RNA ligand that selectively blocks E2F function. Nat. Med., 2, 1386–1389.
9.
JENISONR.D., GILLS.C., PARDIA., and POLISKYB. (1994). High-resolution molecular discrimination by RNA. Science, 263, 1425–1429.
10.
JINH., and ZANGARR.C. (2009). Protein modifications as potential biomarkers in breast cancer. Biomark Insights, 4, 191–200.
11.
KAZANECKIC.C., KOWALSKIA.J., DINGT., RITTLINGS.R., and DENHARDTD.T. (2007). Characterization of anti-osteopontin monoclonal antibodies: Binding sensitivity to post-translational modifications. J. Cell Biochem., 102, 925–935.
12.
KELLERA., NESVIZHSKIIA.I., KOLKERE., and AEBERSOLDR. (2002). Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. Anal. Chem., 74, 5383–5392.
13.
KIMW., BENNETTE.J., HUTTLINE.L., GUOA., LIJ., POSSEMATOA., SOWAM.E., RADR., RUSHJ., COMBM.J., et al. (2011). Systematic and quantitative assessment of the ubiquitin-modified proteome. Mol. Cell, 44, 325–340.
14.
KOMANDERD. (2009). The emerging complexity of protein ubiquitination. Biochem. Soc. Trans., 37, 937–953.
15.
LAMMERSM., NEUMANNH., CHINJ.W., and JAMESL.C. (2010). Acetylation regulates cyclophilin A catalysis, immunosuppression and HIV isomerization. Nat. Chem. Biol., 6, 331–337.
16.
MCDONALDW.H., and YATESJ.R.3RD (2002) Shotgun proteomics and biomarker discovery. Dis. Markers, 18, 99–105.
17.
NESVIZHSKIIA.I., KELLERA., KOLKERE., and AEBERSOLDR. (2003). A statistical model for identifying proteins by tandem mass spectrometry. Anal. Chem., 75, 4646–4658.
18.
RAYP., RIALON-GUEVARAK.L., VERASE., SULLENGERB.A., and WHITER.R. (2012). Comparing human pancreatic cell secretomes by in vitro aptamer selection identifies cyclophilin B as a candidate pancreatic cancer biomarker. J. Clin. Invest., 122, 1734–1741.
SHAHBAZIANM.D., and GRUNSTEINM. (2007). Functions of site-specific histone acetylation and deacetylation. Annu. Rev. Biochem., 76, 75–100.
21.
SINCHAIKULS., HONGSACHARTP., SRIYAMS., TANTIPAIBOONWONGP., PHUTRAKULS., and CHENS.T. (2008). Current proteomic analysis and post-translational modifications of biomarkers in human lung cancer materials. Chang Gung Med. J., 31, 417–430.
22.
STRIETERE.R., and KORASICKD.A. (2012). Unraveling the complexity of ubiquitin signaling. ACS Chem. Biol., 7, 52–63.
SUNDARARAJANN., MAOD., CHANS., KOOT.W., SUX., SUNL., ZHANGJ., SUNGK.B., YAMAKAWAM., GAFKENP.R., et al. (2006). Ultrasensitive detection and characterization of posttranslational modifications using surface-enhanced Raman spectroscopy. Anal. Chem., 78, 3543–3550.
25.
TAUSSIGM.J., STOEVESANDTO., BORREBAECKC.A., BRADBURYA.R., CAHILLD., CAMBILLAUC., DEDARUVAR, A., DUBELS., EICHLERJ., FRANKR., et al. (2007). ProteomeBinders: planning a European resource of affinity reagents for analysis of the human proteome. Nat. Methods, 4, 13–17.
26.
TUERKC., and GOLDL. (1990). Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science, 249, 505–510.
27.
UHLENM. (2007). Mapping the human proteome using antibodies. Mol. Cell Proteomics, 6, 1455–1456.
28.
WAGNERS.A., BELIP., WEINERTB.T., NIELSENM.L., COXJ., MANNM., and CHOUDHARYC. (2011). A proteome-wide, quantitative survey of in vivo ubiquitylation sites reveals widespread regulatory roles. Mol. Cell Proteomics 10, M111. 013284.
29.
WEINERTB.T., IESMANTAVICIUSV., WAGNERS.A., SCHOLZC., GUMMESSONB., BELIP., NYSTROMT., and CHOUDHARYC. (2013). Acetyl-phosphate is a critical determinant of lysine acetylation in E. coli. Mol. Cell, 51, 265–272.
30.
WILKINSONK.D. (1987). Protein ubiquitination: a regulatory post-translational modification. Anticancer Drug Des., 2, 211–229.
31.
WILLIAMSB.A., LINL., LINDSAYS.M., and CHAPUTJ.C. (2009). Evolution of a histone H4-K16 acetyl-specific DNA aptamer. J. Am. Chem. Soc., 131, 6330–6331.
32.
YUB.J., KIMJ.A., MOONJ.H., RYUS.E., and PANJ.G. (2008). The diversity of lysine-acetylated proteins in Escherichia coli. J. Microbiol. Biotechnol., 18, 1529–1536.
33.
ZHANGK., ZHENGS., YANGJ.S., CHENY., and CHENGZ. (2013). Comprehensive profiling of protein lysine acetylation in Escherichia coli. J. Proteome Res., 12, 844–851.
34.
ZHAOJ., XINM., WANGT., ZHANGY., and DENGX. (2009). Nicotine enhances the antiapoptotic function of Mcl-1 through phosphorylation. Mol. Cancer Res., 7, 1954–1961.
35.
ZICHELR., CHEARWAEW., PANDEYG.S., GOLDINGB., and SAUNAZ.E. (2012). Aptamers as a sensitive tool to detect subtle modifications in therapeutic proteins. PLoS One, 7, e31948.
